OncoCyte (NASDAQ:OCX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of OncoCyte (NASDAQ:OCX) in a report issued on Thursday. The firm set a “sell” rating on the stock.

Separately, Needham & Company LLC reiterated a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a report on Wednesday.

OncoCyte Price Performance

Shares of NASDAQ OCX opened at $2.94 on Thursday. OncoCyte has a twelve month low of $2.29 and a twelve month high of $4.34. The firm has a 50-day moving average of $3.04 and a two-hundred day moving average of $2.98.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.54). The company had revenue of $0.12 million for the quarter. OncoCyte had a negative return on equity of 237.81% and a negative net margin of 6,122.29%. During the same quarter in the previous year, the firm posted ($0.57) EPS.

Insiders Place Their Bets

In related news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was bought at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the acquisition, the insider now owns 6,244,405 shares in the company, valued at $18,420,994.75. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, major shareholder Broadwood Partners, L.P. acquired 1,315,339 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was purchased at an average cost of $2.95 per share, for a total transaction of $3,880,250.05. Following the completion of the transaction, the insider now directly owns 6,244,405 shares in the company, valued at $18,420,994.75. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Andrea S. James acquired 33,670 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was purchased at an average price of $2.97 per share, with a total value of $99,999.90. Following the completion of the transaction, the chief financial officer now owns 33,670 shares of the company’s stock, valued at approximately $99,999.90. The disclosure for this purchase can be found here. Corporate insiders own 1.58% of the company’s stock.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.